2026 data ClinicalTrials.gov official source

Conditions: F

Every condition beginning with F that has a registered US clinical trial, with how many studies cover each.

827 conditions starting with "F"

Showing 101–150 of 827

Condition Trials
Fallopian Tube Neoplasms 12
Fallopian Tube Patency Tests 1
Fallopian Tube Serous Adenocarcinoma 9
Fallopian Tube Serous Neoplasm 1
Fallopian Tube Transitional Cell Carcinoma 8
Fallopian Tube Undifferentiated Carcinoma 5
Falls 8
Falls Injury 1
Falls with Injuries 1
Falls, Balance Self-confidence 1
Falls, Intervention 1
Falls-Risk 2
Familial Adenomatous Polyposis 11
Familial Adenomatous Polyposis (FAP) 1
Familial Alcoholism Vulnerability 1
Familial Amyloid Polyneuropathy 1
Familial Amyloidosis 1
Familial Amyloidotic Cardiomyopathy (FAC) 1
Familial ATTR-CM (ATTRm-CM, or FAC) 1
Familial Atypical Multiple Mole-Melanoma 2
Familial Cancer 1
Familial Chylomicronemia 1
Familial Chylomicronemia Syndrome 5
Familial Cold Autoinflammatory Syndrome 1
Familial Dilated Cardiomyopathy 1
Familial Dysautonomia 2
Familial Dysautonomia (Riley-Day Syndrome) 1
Familial Fatal Insomnia 1
Familial Frontotemporal Dementia 1
Familial Frontotemporal Lobar Degeneration (fFTLD) 1
Familial Hemophagocytic Lymphocytosis 1
Familial Hemophagocytic Lymphohistiocytosis 1
Familial Hemophagocytic Lymphohistiocytosis (FLH) 1
Familial Hypercholesterolaemia 2
Familial Hypercholesterolemia 8
Familial Hypercholesterolemia - Heterozygous 1
Familial Hypercholesterolemia - Homozygous 2
Familial Interstitial Pneumonia 1
Familial Isolated Hyperparathyroidism 1
Familial Male-Limited Precocious Puberty (FMPP) 1
Familial Mediterranean Fever 2
Familial Mediterranean Fever (FMF) 1
Familial Pancreatic Cancer 3
Familial Partial Lipodystrophy 3
Familial Platelet Disorder 1
Familial Platelet Disorder With Predisposition to Myeloid Malignancies 1
Familial Pulmonary Fibrosis 2
Familial Renal Cancer (FRC) 1
Familial Thrombotic Thrombocytopenic Purpura 1
Familial Tumoral Calcinosis 1

Related

Data sourced from official public datasets. See our methodology for details.